TERN – Terns Pharmaceuticals Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Recommendation Rating

2.33

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 15

Low: 11

High: 19

Total Analysts: 6

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.

We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan

Related shariah Compliant stocks

🔒